WHAT IS CLAIMED IS:

1. A method of radiative therapy comprising:

a) introducing more than one magnetic component particle into a patient;

b) magnetically guiding with a non-alternating magnetic field the magnetic component particle to a targeted site; and

d) depositing energy at the targeted site.

2. The method of Claim 1, wherein the magnetic component particle comprises a metal with more than 75% metallic iron.

3. The method of Claim 1, wherein iron in the magnetic component particle is less than 10% iron oxide.

4. The method of Claim 1, wherein the magnetic component particles comprises a magnetosorptive particle.

5. The method of Claim 4, wherein the magnetosorptive particle has a weight ratio of magnetic component:sorbent in the range from about 95:5 to about 50:50.

6. The method of Claim 4, wherein the magnetosorptive composition comprises magnetocarbon particles.

7. The method of Claim 6, wherein the magnetocarbon particles comprise at least one type of activated carbon, selected from the group consisting of type A, type B, type E, type K, and type KB.

8. The method of Claim 6, wherein the magnetocarbon particles further comprise one or more biologically active agents.

9. The method of Claim 8, wherein the one or more biologically active agents are selected from the group consisting of antibiotics, antifungals and antineoplastic agents.

10. The method of Claim 4, wherein the magnetosorptive composition comprises magnetoceramic particles.

11. The method of Claim 10, wherein the ceramic is selected from the group consisting of a natural porous adsorptive material and a synthetic porous adsorptive material.

12. The method of Claim 10, wherein the ceramic is selected from the group consisting of hydroxyapatite, silicas and chemically modified silicas.

13. The method of Claim 10, wherein the magnetoceramic particles further comprise one or more biologically active agents.

14. The method of Claim 13, wherein the one or more biologically active agents are chosen from the group consisting of antifungals, antineoplastics and antibiotics.

15. The method of Claim 1, wherein the magnetic component particles are magnetopolymer particles.

16. The method of Claim 15, wherein the polymeric components are biodegradable polymers.

17. The method of Claim 16, wherein the polymeric component is PLGA.

18. The method of Claim 15, wherein the magnetopolymer particles further comprise one or more biologically active agents.

19. The method of Claim 15, wherein the one or more biologically active agents are chosen from the group consisting of antifungal, antineoplasic and antibiotics.

20. The method of Claim 1, wherein the magnetic component particles are processed.

21. The method of Claim 20, wherein the process is selected from the group consisting of gas phase treatment, mechanical milling, spray drying, heating, cooling, annealing, and plastic deformation.

22. The method of Claim 1, where the magnetic component particles further comprise one or more biologically active agents that are one or more isotopes.

23. The method of Claim 1, wherein one or more biologically active bifunctional agent are attached to the particles.

24. The method of Claim 1, wherein the size of the particles is less than 5 cm.

25. The method of Claim 24, wherein the average size of the particles in the magnetic composition is between approximately 0.1 microns to approximately 20 microns.

26. The method of Claim 24, wherein the average size of the particle is from between about 0.5 to about 5 microns.

27. The method of Claim 1, wherein the magnetic component particles are introduced with a delivery vehicle.

28. The method of Claim 1, wherein the magnetic component particles are introduced with one or more excipients.

29. The method of Claim 1, wherein the particles are introduced by a method selected from the group consisting of injection, infusion, implantation, and ingestion.

30. The method of Claim 1, wherein the targeted site is selected from the group consisting of tumors, infections, aneurysms, abscesses, viral growths, and other focal points of disease.

31. The method of Claim 1, also comprising the introduction of an embolic agent.

32. The method of Claim 32, wherein the embolic agent is a second batch of magnetic component particles, wherein the larger particles are used as the embolic agent.

33. The method of Claim 1, wherein the deposited energy is applied for an amount of time effective to obtain a therapeutic effect.

34. The method of Claim 1, wherein protective compositions are used in the area surrounding the target.

35. The method of Claim 1, wherein the deposited energy is applied with a RF capacitive heating system.

36. The method of Claim 1, wherein the deposited energy is tunable.

37. The method of Claim 1, wherein the deposited energy is electrical.

38. The method of Claim 1, wherein the deposited energy is alternating magnetic energy.

39. The method of Claim 1, wherein the deposited energy is nuclear.

40. The method of Claim 39, wherein the nuclear energy is from gamma particles.

41. The method of Claim 39, wherein the nuclear energy is from beta particles.

42. The method of Claim 39, wherein the nuclear energy is from alpha particles.

43. The method of Claim 39, wherein the nuclear energy is from neutrons.

44. The method of Claim 43, wherein the neutrons are used for neutron capture therapy.

45. The method of Claim 39, wherein the deposited energy is from heavy particles.

46. The method of Claim 39, wherein the deposited energy is from a particle beam.

47. The method of Claim 1, wherein the deposited energy is absorbed by the magnetic component particles and causes the release of one or more biologically active agents from the particles.

48. The method of Claim 1, wherein the deposited energy is photon related.

49. The method of Claim 1, wherein the deposited energy causes a beneficial rise or fall in local temperature.

50. The method of Claim 1, wherein the deposited energy is ultrasound.

51. The method of Claim 1, wherein magnetic component particles further comprises a biologically active agent.

52. A kit for administering radiative therapy, comprising:

b) a unit dose of magnetic component particles;

b) a non-alternating magnet for guiding said particles to a target in the patient once administered to the patient;

c) a source of energy that will deposit energy into the patient once the magnetic component particles have been administered to the patient and magnetically guided to the target;

d) optionally one or more receptacles and instructions for use.

53. The kit of Claim 52, wherein the magnetic component particles comprises less than 10% iron oxide.

54. The kit of Claim 52, wherein the magnetic component particles comprise a metal with more than 75% metallic iron.

55. The kit of Claim 52, wherein the magnetic component particles comprise magnetocarbon particles.

56. The kit of Claim 52, wherein the magnetic component particles comprise magnetoceramic particles.

57. The kit of Claim 52, wherein the magnetic component particles comprise magneto-polymer magnetic component particles.

58. The kit of Claim 52, wherein the magnetic component particles further comprise one or more biologically active agents.

59. The kit of Claim 58, wherein the one or more biologically active agents are chosen from the group consisting of antifungals, antineoplastics and antibiotics.

60. The kit of Claim 52, also comprising an embolic agent.

61. The kit of Claim 52, wherein the source of energy is a RF capacitive heating system.

62. The kit of Claim 52, wherein the source of energy is tunable.

63. The kit of Claim 52, wherein the source of energy is a source of neutrons.

64. The kit of Claim 52, wherein the source of energy is a source of gamma rays.

65. The kit of Claim 52, wherein the source of energy is a source of beta particles.

66. The kit of Claim 52, wherein the source of energy is a source of alpha particles.

67. The kit of Claim 52, wherein the source of energy is a source of heavy particles.

68. The kit of Claim 52, wherein the source of energy is a particle beam.

69. The kit of Claim 52, wherein the source of energy is a source of electrical energy.

70. The kit of Claim 52, wherein the source of energy is a source of alternating magnetic energy.

71. The kit of Claim 52, wherein the source of energy is a source of photons.

72. A targetable particle comprising a magnetic component other than metallic iron and either carbon or ceramic material.

73. The targetable particle of Claim 72, wherein the particle is a carbon –bearing particle.

74. The targetable particle of Claim 73, wherein the carbon is chosen from the group consisting of activated carbon type A, type B, type E, type K, and typeKB.

75. The targetable particle of Claim 73, wherein the magnetic component is chosen from the group consisting of nickel, cobalt, awaruite, wairauite, pyrrhotite, greigite, troilite, yttrium iron garnet, Alnico 5, Alnico 5 DG, Sm_2Co_{17}, $SmCo_5$, and NdFeB components.

76. The targetable particle of Claim 73, wherein the magnetic component is chosen from the group consisting of nickel, cobalt, awaruite, wairauite, pyrrhotite, greigite, troilite, and yttrium iron garnet components.

77. The targetable particle of Claim 74, further comprising one or more biologically active agents.

78. The targetable particle of Claim 77 wherein the one or more biologically active agents are chosen from the group consisting of antifungals, antibiotics and antineoplastic agents.

79. The targetable particle of Claim 72, wherein the particle is a ceramic-bearing particle.

80. The targetable particle of Claim 79, wherein the ceramic material is silica, octadecyl silica or other chemically modified silica, or hydroxyapatite.

81. The targetable particle of Claim 79, wherein the magnetic component is chosen from the group consisting of nickel, cobalt, awaruite, wairauite, pyrrhotite, greigite, troilite, yttrium iron garnet, Alnico 5, Alnico 5 DG, Sm_2Co_{17}, $SmCo_5$, and NdFeB components.

82. The targetable particle of Claim 79, wherein the magnetic component is chosen from the group consisting nickel, cobalt, awaruite, wairauite, pyrrhotite, greigite, troilite, and yttrium iron garnet components.

83. The targetable particle of Claim 79, further comprising one or more biologically active agents.

84. The targetable particle of Claim 83, wherein the one or more biologically active agents are chosen from the group consisting of antifungals, antibiotics and antineoplastic agents.

85. The targetable particle of Claim 72, further comprising one or more biologically active agents.

86. The targetable particle of Claim 85, wherein the one or more biologically active agents is chosen from the group consisting of antifungal, antibiotic and antineoplastic agents.

87. The targetable particle of Claim 72, further comprising one or more excipients.

88. The targetable particle of Claim 72, further comprising one or more delivery vehicles.

89. The targetable particle of Claim 72 in a unit dose form.